Definition
A neurodegenerative disease of the brain characterized clinically by insidious, chronic, and progressive cognitive decline, and histologically by cerebral accumulations of the proteins beta amyloid (plaques) and tau (tangles).
Historical Background
In 1902, a woman called Auguste D. came under the care of Dr. Alois Alzheimer, then at the University of Frankfurt. The patient manifested changes in behavior and cognition. Her clinical course was characterized by progressive paranoia, delusional thinking, disorientation, and poor memory. She was institutionalized for the last 3 years of her life. Upon her death, Alzheimer analyzed her brain using a silver stain, and described both extracellular and intracellular protein accumulations. The extracellular protein accumulations were termed plaques and the intraneuronal protein accumulations were called tangles. Alzheimer presented the results of this autopsy in 1906. Several other similar cases of relatively “presenile” (i.e.,...
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Readings
Amaducci, L. A., Rocca, W. A., & Schoenberg, B. S. (1986). Origin of the distinction between Alzheimer’s disease and senile dementia: how history can clarify nosology. Neurology, 36, 1497–1499.
Blacker, D., & Tanzi, R. E. (1998). The genetics of Alzheimer disease: current status and future prospects. Archives of Neurology, 55, 294–296.
Blessed, G., Tomlinson, B., & Roth, M. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. The British Journal of Psychiatry, 114, 797–811.
Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., et al. (1999). Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. The American Journal of Human Genetics, 65, 664–670.
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261, 921–923.
De Leon, M. J., & Klunk, W. (2005). Biomarkers for the early diagnosis of Alzheimer’s disease. Lancet Neurology, 5, 198–199.
Evans, D. A., Funkenstein, H. H., Albert, M. S., Scherr, P. A., Cook, N. R., Chown, M. J., et al. (1989). Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA, 262, 2551–2556.
Gearing, M., Mirra, S. S., Hedreen, J. C., Sumi, S. M., Hansen, L. A., & Heyman, A. (1995). The Consortium to establish a registry for Alzheimer’s disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology, 45, 461–466.
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., et al. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64, 1553–1562.
Hardy, J., & Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends in Pharmacological Sciences, 12, 383–388.
Hardy, J. A., & Higgins, G. A.(1992). Alzheimer’s disease: the amyloid cascade hypothesis. Science, 256, 184–185.
Katzman, R. (1976). The prevalence and malignancy of Alzheimer’s disease: a major killer. Archives of Neurology, 33, 217–218.
Khachaturian, Z. S. (1985). Diagnosis of Alzheimer’s disease. Archives of Neurology, 42, 1097–1106.
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Annals of Neurology, 55, 306–319.
Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., et al. (1998). Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. The New England Journal of Medicine, 338, 506–511.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939–944.
Morris, J. C. (2006). Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Archives of Neurology, 63, 15–16.
Mosconi, L., De Santi, S., Li, J., Tsui, W. H., Li, Y., Boppana, M., et al. (2007). Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2006.12.008.
National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. (1997). Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiology of Aging, 18(4 Suppl.), S1–2.
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology, 56, 303–308.
Petersen, R. C., Thomas, R. G., Grundman, M, Bennett, D., Doody, R., Ferris, S., et al. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. The New England Journal of Medicine, 352, 2379–2388.
Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on AgingWork Group. (1998). Consensus report of the work group on: molecular and biochemical markers of Alzheimer’s disease. Neurobiology of Aging, 19, 109–116.
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. The New England Journal of Medicine, 336, 1216–1222.
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., et al. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Medicine, 2, 864–870.
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., et al. (2006). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine, 355, 1525–1538.
Snowdon, D. A., Kemper, S. J., Mortimer, J. A., Greiner, L. H., Wekstein, D. R., & Markesbery, W. R. (1996). Linguistic ability in early life and cognitive function and Alzheimer’s disease in late life. Findings from the Nun Study. JAMA, 275, 528–532.
Swerdlow, R. H. (2007). Is aging part of Alzheimer’s disease, or is Alzheimer’s disease part of aging? Neurobiology of Aging, 28, 1465–1480.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this entry
Cite this entry
Swerdlow, R.H., Anderson, H., Burns, J.M. (2011). Alzheimer’s Disease. In: Kreutzer, J.S., DeLuca, J., Caplan, B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-79948-3_290
Download citation
DOI: https://doi.org/10.1007/978-0-387-79948-3_290
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-79947-6
Online ISBN: 978-0-387-79948-3
eBook Packages: Behavioral Science